Nadira Duraković, Zinaida Perić, Sandra Bašić Kinda, Lana Desnica, Dino Dujmović, Ivo Radman Livaja, Ranka Serventi Seiwerth, Igor Aurer, Radovan Vrhovac
{"title":"同种异体干细胞移植前完全缓解对霍奇金淋巴瘤无进展生存期的影响。","authors":"Nadira Duraković, Zinaida Perić, Sandra Bašić Kinda, Lana Desnica, Dino Dujmović, Ivo Radman Livaja, Ranka Serventi Seiwerth, Igor Aurer, Radovan Vrhovac","doi":"10.2991/chi.k.210704.002","DOIUrl":null,"url":null,"abstract":"Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potential curative option for patients suffering from relapsed/ refractory (r/r) Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT), offering a survival advantage over standard chemotherapy approaches [1]. However, two recently approved new drug treatments for r/r HL after ASCT [antiCD30 antibody-drug conjugate, brentuximab-vedotin (BV) and immune-checkpoint inhibitors (ICI)], demonstrated long-term disease control, with 38% and 16% of patients achieving complete response (CR), respectively [2]. These results have lately triggered much debate whether patients need to undergo alloHSCT at all after achieving response with BV or ICI [3,4].","PeriodicalId":10368,"journal":{"name":"Clinical Hematology International","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/34/CHI-3-3-116.PMC8486971.pdf","citationCount":"1","resultStr":"{\"title\":\"The Impact of Achieving Complete Remission Prior to Allogeneic Stem Cell Transplantation on Progression-Free Survival in Hodgkin Lymphoma.\",\"authors\":\"Nadira Duraković, Zinaida Perić, Sandra Bašić Kinda, Lana Desnica, Dino Dujmović, Ivo Radman Livaja, Ranka Serventi Seiwerth, Igor Aurer, Radovan Vrhovac\",\"doi\":\"10.2991/chi.k.210704.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potential curative option for patients suffering from relapsed/ refractory (r/r) Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT), offering a survival advantage over standard chemotherapy approaches [1]. However, two recently approved new drug treatments for r/r HL after ASCT [antiCD30 antibody-drug conjugate, brentuximab-vedotin (BV) and immune-checkpoint inhibitors (ICI)], demonstrated long-term disease control, with 38% and 16% of patients achieving complete response (CR), respectively [2]. These results have lately triggered much debate whether patients need to undergo alloHSCT at all after achieving response with BV or ICI [3,4].\",\"PeriodicalId\":10368,\"journal\":{\"name\":\"Clinical Hematology International\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/34/CHI-3-3-116.PMC8486971.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Hematology International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2991/chi.k.210704.002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Hematology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2991/chi.k.210704.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
The Impact of Achieving Complete Remission Prior to Allogeneic Stem Cell Transplantation on Progression-Free Survival in Hodgkin Lymphoma.
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potential curative option for patients suffering from relapsed/ refractory (r/r) Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT), offering a survival advantage over standard chemotherapy approaches [1]. However, two recently approved new drug treatments for r/r HL after ASCT [antiCD30 antibody-drug conjugate, brentuximab-vedotin (BV) and immune-checkpoint inhibitors (ICI)], demonstrated long-term disease control, with 38% and 16% of patients achieving complete response (CR), respectively [2]. These results have lately triggered much debate whether patients need to undergo alloHSCT at all after achieving response with BV or ICI [3,4].
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
